Agios' late-stage Pyrukynd tri­al in kids with rare blood dis­or­der miss­es pri­ma­ry end­point

Agios’ first-ever pe­di­atric da­ta read­out missed the pri­ma­ry end­point, with its drug Pyrukynd (mi­tapi­vat) not show­ing sta­tis­ti­cal sig­nif­i­cance in chil­dren with pyru­vate ki­nase (PK) de­fi­cien­cy …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER